Global Information
회사소개 | 문의 | 위시리스트

원발성 경화성 담관염 : 파이프라인 리뷰

Primary Sclerosing Cholangitis - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 246021
페이지 정보 영문 115 Pages
가격
US $ 2,000 ₩ 2,308,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,616,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,924,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


원발성 경화성 담관염 : 파이프라인 리뷰 Primary Sclerosing Cholangitis - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 115 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

원발성 경화성 담관염(PSC)은 만성 간질환으로 염증을 수반하는 진행성 담즙울체, 간내·간외 총간담관의 섬유화라는 특징이 있습니다. 주요 증상으로 복통, 오한, 설사, 권태감, 가려움, 체중 감소 등을 들 수 있습니다. 주요 질병 소질에는 연령과 염증성 장질환 등이 포함됩니다. 주요 치료법으로는 항생물질, 항히스타민제, 담즙산 결합제 등이 있습니다.

세계 각국에서의 원발성 경화성 담관염(PSC : Primary Sclerosing Cholangitis) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 조사 결과를 전해드립니다.

목차

서론

  • 분석 범위

원발성 경화성 담관염 개요

치료제 개발

  • 원발성 경화성 담관염용 파이프라인 제품 : 개요
  • 원발성 경화성 담관염용 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

파이프라인 제품 개요

  • 임상시험 단계 제품

기업에서 개발중인 제품

치료제 개발에 참여하고 있는 기업

  • Biotie Therapies Corp.
  • ChemoCentryx, Inc.
  • Dr. Falk Pharma GmbH
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Shire Plc

치료제 평가

  • 단독치료 제품
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • BTT-1023
  • CCX-507
  • norursodeoxycholic acid
  • obeticholic acid
  • SHP-625
  • simtuzumab

최근의 파이프라인 동향

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 15.08.28

List of Tables

  • Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Nyrada Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Pliant Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Primary Sclerosing Cholangitis - Dormant Projects, H1 2019
  • Primary Sclerosing Cholangitis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 2, 11 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Primary Sclerosing Cholangitis - Overview
  • Primary Sclerosing Cholangitis - Therapeutics Development
  • Primary Sclerosing Cholangitis - Therapeutics Assessment
  • Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
  • Primary Sclerosing Cholangitis - Drug Profiles
  • Primary Sclerosing Cholangitis - Dormant Projects
  • Primary Sclerosing Cholangitis - Discontinued Products
  • Primary Sclerosing Cholangitis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q
 
BCC Research